Nathan Stanton
Medical · Opelika, ALNPI 1265534069
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,527 of the $5,633 with a category attached, or 80.4%. 31 manufacturers reported payments, led by Axonics, Inc. at 32.8% of the total. Reporting peaked in 2022 at $2,546 and has fallen 79.0% since, to $535 in 2025. Among medical clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 213 payments — averaging $26.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$2K
- Sumitomo Pharma America, Inc.$441
- Astellas Pharma US Inc$422
- Myriad Genetic Laboratories, Inc.$361
- Johnson & Johnson$328
- Myovant Sciences Inc.$275
- plus $2K from 25 others
What the payments were for
- Travel & lodging$85115%
- Food & beverage$4,52780%
- Education$2555%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 29 | $1,845 |
| Sumitomo Pharma America, Inc. | 25 | $441 |
| Astellas Pharma US Inc | 18 | $422 |
| Myriad Genetic Laboratories, Inc. | 17 | $361 |
| Johnson & Johnson(2 entities) | 16 | $328 |
| Myovant Sciences Inc. | 19 | $275 |
| Pfizer | 12 | $250 |
| AbbVie(2 entities) | 19 | $240 |
| Teleflex LLC | 3 | $178 |
| Progenics Pharmaceuticals, Inc. | 7 | $158 |
| Medtronic | 4 | $150 |
| Dendreon Pharmaceuticals LLC | 4 | $132 |
| Endo Pharmaceuticals Inc. | 6 | $122 |
| Olympus America Inc. | 4 | $98 |
| Coloplast | 5 | $85 |
| Urovant Sciences Inc | 5 | $79 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $65 |
| 180 Medical, Inc. | 2 | $54 |
| Urogen Pharma, Inc. | 3 | $50 |
| Tolmar Pharmaceuticals, Inc. | 2 | $37 |
| Intuitive Surgical | 1 | $34 |
| Convatec Inc. | 2 | $34 |
| Ferring Pharmaceuticals Inc. | 1 | $30 |
| Blue Earth Diagnostics | 1 | $26 |
| Endo USA, Inc. | 1 | $24 |
| Calyxo, Inc. | 1 | $24 |
| Rochester Medical Corporation | 1 | $23 |
| Procept Biorobotics Corporation | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Tolmar, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,633 in reported general payments places this provider in the 90th percentile of 175 medical providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 18 | $223,633 |
| ErleadaApalutamide | 12 | $174,677 |
| MyrbetriqMirabegron | 122 | $68,963 |
| GemtesaVibegron | 88 | $63,823 |
| Tamsulosin Hcl | 310 | $3,990 |
| Tolterodine Tartrate ErTolterodine Tartrate | 11 | $2,404 |
| Estradiol | 26 | $1,910 |
| Finasteride | 118 | $1,740 |
| Oxybutynin Chloride ErOxybutynin Chloride | 52 | $846 |
| Cephalexin | 14 | $54 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $22 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $422 | $292,596140 claims |
| Johnson & JohnsonErleada | $328 | $174,67712 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $441 | $63,82388 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 175 medical providers in Alabama.
Other medical in Opelika
- Lindsey MangumFlorence$44K
- Jaime DunnBirmingham$16K
- Stacy RichersonMobile$12K
- Susannah CashAuburn$11K
- Deana PorterAuburn$9K
- Rachel ThompsonFairhope$9K
- Shelley WinzelerHomewood$8K
- Reiga EvansHuntsville$8K
- Lillian ShafferCullman$8K
- Lauren TidwellHuntsville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.